Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

CVKD

Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CVKD
DatumZeitQuelleÜberschriftSymbolFirma
12/06/202422h10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202423h27Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202423h25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
03/06/202415h00PR Newswire (US)Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
29/05/202423h27Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
23/05/202415h00PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/05/202415h00PR Newswire (US)Cadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
09/05/202412h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
11/04/202422h30PR Newswire (US)Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/04/202415h00PR Newswire (US)Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsNASDAQ:CVKDCadrenal Therapeutics Inc
11/03/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
11/03/202414h00PR Newswire (US)Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
05/03/202423h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
26/02/202415h00PR Newswire (US)Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
15/02/202414h00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CVKDCadrenal Therapeutics Inc
12/02/202422h49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
08/02/202415h00PR Newswire (US)Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialNASDAQ:CVKDCadrenal Therapeutics Inc
31/01/202415h00PR Newswire (US)Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsNASDAQ:CVKDCadrenal Therapeutics Inc
24/01/202415h00PR Newswire (US)Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
04/01/202415h00PR Newswire (US)Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
19/12/202315h00PR Newswire (US)Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetNASDAQ:CVKDCadrenal Therapeutics Inc
12/12/202315h00PR Newswire (US)Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationNASDAQ:CVKDCadrenal Therapeutics Inc
30/11/202322h15PR Newswire (US)Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:CVKDCadrenal Therapeutics Inc
09/11/202315h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
09/11/202315h00PR Newswire (US)Cadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
09/11/202314h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
23/10/202323h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
09/10/202322h15PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
08/09/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
05/09/202314h00PR Newswire (US)Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressNASDAQ:CVKDCadrenal Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CVKD

Kürzlich von Ihnen besucht

Delayed Upgrade Clock